pentoxifylline has been researched along with 2019 Novel Coronavirus Disease in 13 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Having the potential role in suppressing inflammation, immune modulation, antiviral and improving respiratory symptoms, this review discusses the potential role of methylxanthine drugs like pentoxifylline and caffeine in the management of COVID-19 patients." | 5.05 | Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 therapeutic strategies? A ray of hope in the midst of the pandemic. ( Al-Mahmood Siddiquee, A; Hashemian, F; Monji, F, 2020) |
| "We have previously described that pentoxifylline alone, or in combination with oxypurinol, reduces the systemic inflammation caused by experimentally-induced pancreatitis in rats." | 3.96 | Pentoxifylline and Oxypurinol: Potential Drugs to Prevent the ( Franco, L; López-Iranzo, FJ; López-Rodas, AM; López-Rodas, G, 2020) |
| "Pentoxifylline (PTX) has broad-spectrum properties such as anti-inflammatory, anticoagulant, and antiviral effects." | 3.01 | Pentoxifylline effects on hospitalized patients with COVID19: A randomized, double-blind clinical trial. ( Azizi, H; Fallah, S; Ghazaeian, M; Karimpour-Razkenari, E; Rouhani, N; Saeedi, M; Salehifar, E; Shaki, F, 2021) |
| "Pentoxifylline treatment was associated with a 64." | 3.01 | Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: Results from an external pilot study. ( Chávez-Alderete, J; Hernandez-Ramírez, C; Jiménez-Villalba, YZ; Loza-Mejía, MA; Maldonado, V; Molina-Sánchez, JR; Oliva-Pérez, EA; Pimentel-González, JF; Sánchez-Martínez, CO, 2021) |
| "Pentoxifylline is a methyl-xanthine derivative and it inhibits the phosphodiesterase IV (PDE IV)." | 2.66 | Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy? ( Fattahi, N; Goodarzi, A; Hanifiha, M; Mozafarpoor, S; Sadeghzadeh-Bazargan, A; Seirafianpour, F, 2020) |
| "Although most patients with coronavirus disease 2019 (COVID-19) have a good prognosis, in some cases, the disease progresses rapidly, and the mortality rate is high." | 2.66 | Potential usefulness of pentoxifylline, a non-specific phosphodiesterase inhibitor with anti-inflammatory, anti-thrombotic, antioxidant, and anti-fibrogenic properties, in the treatment of SARS-CoV-2. ( Amezcua-Guerra, LM; Arias-Mendoza, A; González-Pacheco, H; Sandoval, J, 2020) |
| "Pentoxifylline is an immunomodulator with anti-inflammatory properties." | 2.66 | Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients. ( Arnold, AD; Arnold, J; Hendry, BM; Manglam, V; Rosen, SD; Sangwaiya, A; Stafford, N, 2020) |
| "Pentoxifylline (PTX) is a phosphodiesterase inhibitor that increases cyclic adenosine monophosphate levels, which in turn activate protein kinase, leading to a reduction in the synthesis of proinflammatory cytokines to ultimately influence the renin-angiotensin system (RAS) in vitro by inhibiting angiotensin 1 receptor (AT1R) expression." | 1.56 | Repositioning of pentoxifylline as an immunomodulator and regulator of the renin-angiotensin system in the treatment of COVID-19. ( Chávez-Alderete, J; Loza-Mejía, MA; Maldonado, V, 2020) |
| "Counterproductive lung inflammation and dysregulated thrombosis contribute importantly to the lethality of advanced COVID-19." | 1.56 | Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole. ( Barroso-Aranda, J; DiNicolantonio, JJ, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 13 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azizi, H | 1 |
| Rouhani, N | 1 |
| Shaki, F | 1 |
| Karimpour-Razkenari, E | 1 |
| Ghazaeian, M | 1 |
| Salehifar, E | 1 |
| Saeedi, M | 1 |
| Fallah, S | 1 |
| Feily, A | 1 |
| Daneshpay, K | 1 |
| Alighadr, A | 1 |
| Seirafianpour, F | 1 |
| Mozafarpoor, S | 1 |
| Fattahi, N | 1 |
| Sadeghzadeh-Bazargan, A | 1 |
| Hanifiha, M | 1 |
| Goodarzi, A | 1 |
| Assimakopoulos, SF | 1 |
| Seintis, F | 1 |
| Marangos, M | 1 |
| Maldonado, V | 2 |
| Loza-Mejía, MA | 2 |
| Chávez-Alderete, J | 2 |
| DiNicolantonio, JJ | 1 |
| Barroso-Aranda, J | 1 |
| González-Pacheco, H | 1 |
| Amezcua-Guerra, LM | 1 |
| Sandoval, J | 1 |
| Arias-Mendoza, A | 1 |
| Hendry, BM | 1 |
| Stafford, N | 1 |
| Arnold, AD | 1 |
| Sangwaiya, A | 1 |
| Manglam, V | 1 |
| Rosen, SD | 1 |
| Arnold, J | 1 |
| López-Iranzo, FJ | 1 |
| López-Rodas, AM | 1 |
| Franco, L | 1 |
| López-Rodas, G | 1 |
| Monji, F | 1 |
| Al-Mahmood Siddiquee, A | 1 |
| Hashemian, F | 1 |
| Hernandez-Ramírez, C | 1 |
| Oliva-Pérez, EA | 1 |
| Sánchez-Martínez, CO | 1 |
| Pimentel-González, JF | 1 |
| Molina-Sánchez, JR | 1 |
| Jiménez-Villalba, YZ | 1 |
| Wall, GC | 1 |
| Smith, HL | 1 |
| Trump, MW | 1 |
| Mohr, JD | 1 |
| DuMontier, SP | 1 |
| Sabates, BL | 1 |
| Ganapathiraju, I | 1 |
| Kable, TJ | 1 |
| Cerqueira, SRPS | 1 |
| Deps, PD | 1 |
| Cunha, DV | 1 |
| Bezerra, NVF | 1 |
| Barroso, DH | 1 |
| Pinheiro, ABS | 1 |
| Pillegi, GS | 1 |
| Repsold, TAR | 1 |
| Kurizky, PS | 1 |
| Collin, SM | 1 |
| Gomes, CM | 1 |
4 reviews available for pentoxifylline and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?
Topics: Betacoronavirus; Chemotherapy, Adjuvant; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; | 2020 |
Potential usefulness of pentoxifylline, a non-specific phosphodiesterase inhibitor with anti-inflammatory, anti-thrombotic, antioxidant, and anti-fibrogenic properties, in the treatment of SARS-CoV-2.
Topics: Anti-Inflammatory Agents; Antioxidants; Antiviral Agents; Betacoronavirus; Coronavirus Infections; C | 2020 |
Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Pandemics; Pento | 2020 |
Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 therapeutic strategies? A ray of hope in the midst of the pandemic.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Caffeine; Coronavirus Infections; COVID-19; COVID-19 Drug T | 2020 |
2 trials available for pentoxifylline and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Pentoxifylline effects on hospitalized patients with COVID19: A randomized, double-blind clinical trial.
Topics: Adult; Aged; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Double-Blind Method; Female; Hospi | 2021 |
Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: Results from an external pilot study.
Topics: Aged; Biomarkers; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Female; Humans; L-Lactate D | 2021 |
7 other studies available for pentoxifylline and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
COVID-19: Pentoxifylline as a potential adjuvant treatment.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combinatio | 2020 |
Pentoxifylline and complicated COVID-19: A pathophysiologically based treatment proposal.
Topics: Antibodies, Monoclonal, Humanized; Betacoronavirus; Blood Coagulation Disorders; Coronavirus Infecti | 2020 |
Repositioning of pentoxifylline as an immunomodulator and regulator of the renin-angiotensin system in the treatment of COVID-19.
Topics: Alveolar Epithelial Cells; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Complement Acti | 2020 |
Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole.
Topics: Adenosine A2 Receptor Agonists; Animals; Anti-Inflammatory Agents, Non-Steroidal; Betacoronavirus; C | 2020 |
Pentoxifylline and Oxypurinol: Potential Drugs to Prevent the
Topics: Acute Disease; Animals; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokine Release Syndrome | 2020 |
Pentoxifylline or theophylline use in hospitalized COVID-19 patients requiring oxygen support.
Topics: Adult; COVID-19; Humans; Oxygen; Pentoxifylline; Retrospective Studies; RNA, Viral; SARS-CoV-2; Theo | 2021 |
The influence of leprosy-related clinical and epidemiological variables in the occurrence and severity of COVID-19: A prospective real-world cohort study.
Topics: Adrenal Cortex Hormones; BCG Vaccine; Brazil; Clofazimine; Cohort Studies; COVID-19; COVID-19 Drug T | 2021 |